Trial
NCT01742793
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Yale University
Collaborators
Peter MacCallum Cancer Centre, Australia
Condition
Hodgkin's Lymphoma
Intervention
lenalidomide (Revlimid) and romidepsin (Istodax)
Why stopped
The study was terminated due to withdrawal of institutional support, Phase II never began.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-04